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background: Dual anti-platelet therapy (DAPT) is the current standard treatment after percutaneous coronary intervention (PCI). We aimed 
to investigate the associations between DAPT cessation and MACE due to stopping 1 or both drugs, in an all-comer PCI population undergoing 
contemporary stenting.
Methods: The PARIS (patterns of non-adherence to anti-platelet regiments in stented patients) registry was a prospective observational multicenter 
study of patients undergoing contemporary PCI. Pre-specified categories for DAPT cessation included physician-recommended discontinuation, brief 
interruption for surgery or disruption (due to non-compliance or bleeding). We examined the effect of DAPT cessation on major adverse events (MACE 
- cardiac death, def./prob. stent thrombosis, myocardial infarction and target lesion revascularization).
results: In 5018 patients, overall DAPT cessation was 57.3% and 558 (11.5%) MACE had occurred at 2 years follow-up. All presented hazard 
ratios (table) are adjusted for age, gender, region, stent type, number of stents and ACS diagnosis. DAPT cessation due to stopping 1 or both drugs 
was entered as a time-updated covariate within each mode of DAPT cessation. The results were unchanged after adjusting or stratifying by original 
recommended DAPT duration at discharge.
conclusion: The present analysis suggests that recommended DAPT discontinuation is safe for both drugs, whereas disruption of both drugs 
compared to one carries substantial additional risk.
Variable Hazard ratio 95% CI MACE Events (n) P-value
On DAPT 1.000 413
Discontinuation - 1 drugs 0.627 (0.456, 0.863) 50 0.004
Discontinuation - 2 drugs 1.153 (0.286, 4.651) 2 0.841
Interruption - 1 drugs 1.419 (0.807, 2.494) 13 0.224
Interruption - 2 drugs 1.449 (0.826, 2.539) 13 0.196
Disruption - 1 drugs 1.315 (0.955, 1.812) 45 0.094
Disruption - 2 drugs 2.109 (1.360, 3.269) 22 <0.001
